Kyverna jumps after cell therapy meets main goal of mid-stage study

Shares of drug developer Kyverna Therapeutics KYTX.O rise 25.5% to $11.02 premarket

Co says its experimental cell therapy, miv-cel, for the treatment of a rare movement disorder met the main goal in a mid-stage study

Miv-cel, formerly named KYV-101, is being tested in patients with stiff person syndrome, a rare autoimmune disorder that makes muscles rigid and causes painful spasms, often making it hard to walk or move normally

The 26-person study showed the therapy led to sustained improvement in mobility among patients - KYTX

As of last close, stock has more than doubled YTD